Lovastatin dosage and administration: Difference between revisions

Jump to navigation Jump to search
Line 24: Line 24:
===Dosage in Patients With Renal Impairment===
===Dosage in Patients With Renal Impairment===


In patients with severe [[renal impairment]] (creatinine clearance <30 mL/min), dosage increases above 20 mg/day should only be considered if the expected benefit exceeds the increased risk of [[myopathy]]/[[rhabdomyolysis]].  [see Warnings and Precautions, Skeletal Muscle Effects (5.1) and Clinical Pharmacology, Pharmacokinetics (12.3)].</div><ref name="dailymed.nlm.nih.gov">{{Cite web  | last =  | first =  | title = ALTOPREV (LOVASTATIN) TABLET, EXTENDED RELEASE [SHIONOGI INC.] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=e8b6ccc2-e6e7-45fd-ab66-c312bcbe2b01 | publisher =  | date =  | accessdate = 13 February 2014 }}</ref>
In patients with severe [[renal impairment]] (creatinine clearance <30 mL/min), dosage increases above 20 mg/day should only be considered if the expected benefit exceeds the increased risk of [[myopathy]]/[[rhabdomyolysis]].  [see Warnings and Precautions, Skeletal Muscle Effects (5.1) and Clinical Pharmacology, Pharmacokinetics (12.3)].<ref name="dailymed.nlm.nih.gov">{{Cite web  | last =  | first =  | title = ALTOPREV (LOVASTATIN) TABLET, EXTENDED RELEASE [SHIONOGI INC.] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=e8b6ccc2-e6e7-45fd-ab66-c312bcbe2b01 | publisher =  | date =  | accessdate = 13 February 2014 }}</ref>


==References==
==References==

Revision as of 00:42, 14 February 2014

Lovastatin
ALTOPREV® FDA Package Insert
Indications and Usage
Dosage and Administration
Dosage Forms and Strengths
Contraindications
Warnings and Precautions
Adverse Reactions
Drug Interactions
Use in Specific Populations
Overdosage
Description
Clinical Pharmacology
Nonclinical Toxicology
Clinical Studies
How Supplied/Storage and Handling
Labels and Packages
Clinical Trials on Lovastatin
ClinicalTrials.gov

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sheng Shi, M.D. [2]

Dosage and Administration

Hyperlipidemia (Heterozygous Familial and Nonfamilial) and Mixed Dyslipidemia (Fredrickson Types IIa and IIb)

The recommended dosing range is 20-60 mg/day, in single doses taken in the evening at bedtime.

Elderly Patients

The usual recommended starting dose in elderly patients (age≥65 years) is 20 mg once a day given in the evening at bedtime. Higher doses should be used only after careful consideration of the potential risks and benefits [see Use in Specific Populations (8.5) and Warnings and Precautions, Skeletal Muscle Effects (5.1)].

Co-administration with Other Drugs

Patients Taking Danazol, Diltiazem, Dronedarone, or Verapamil The dose of Altoprev should not exceed 20 mg/day [see Warnings and Precautions, Skeletal Muscle Effects (5.1)].

Patients Taking Amiodarone

The dose of Altoprev should not exceed 40 mg/day. [see Warnings and Precautions, Skeletal Muscle Effects (5.1) and Drug Interactions (7.6)].

Dosage in Patients With Renal Impairment

In patients with severe renal impairment (creatinine clearance <30 mL/min), dosage increases above 20 mg/day should only be considered if the expected benefit exceeds the increased risk of myopathy/rhabdomyolysis. [see Warnings and Precautions, Skeletal Muscle Effects (5.1) and Clinical Pharmacology, Pharmacokinetics (12.3)].[1]

References

  1. "ALTOPREV (LOVASTATIN) TABLET, EXTENDED RELEASE [SHIONOGI INC.]". Retrieved 13 February 2014.

Template:Statins